TokenPost·
Absci Eyes December Hair-Loss Data, Reaffirms Mid-2027 Endometriosis Trial Target
The company expects interim 13-week proof-of-concept findings for ABS-201 in December, followed by full 26-week data in early 2027.
More news
- TokenPostVise Announces Four Long-Short Options for Interactive Brokers Accounts
- TokenPostZealand Pharma Sees $400 Million Net Q4 Cash Inflow Tied to Roche
- TokenPostApplied Optoelectronics Posts $269.9 Million in Q3 Revenue
- crypto.newsGemini reportedly sells UK and EU units to KAST for under $10M
- Crypto BriefingCerebras Systems guides fourth-quarter core revenue to $310M-$330M, well above estimates
- TokenPostDaly Says AI Demand May Ease as Chip Price Concerns Persist